Malaysia

Population 2018: 32 million

Tuberculosis profile

<table>
<thead>
<tr>
<th>Estimates of TB burden*, 2018</th>
<th>Number (thousands)</th>
<th>Rate per 100 000 population</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total TB incidence</td>
<td>29 (25–33)</td>
<td>92 (79–106)</td>
</tr>
<tr>
<td>HIV-positive TB incidence</td>
<td>1.9 (1.6–2.2)</td>
<td>5.9 (5–6.9)</td>
</tr>
<tr>
<td>MDR/RR-TB incidenceººº</td>
<td>0.48 (0.36–0.62)</td>
<td>1.5 (1–2)</td>
</tr>
<tr>
<td>HIV-negative TB mortality</td>
<td>1.2 (1.1–1.4)</td>
<td>3.9 (3.5–4.3)</td>
</tr>
<tr>
<td>HIV-positive TB mortality</td>
<td>0.32 (0.24–0.42)</td>
<td>1 (0.75–1.3)</td>
</tr>
</tbody>
</table>

Estimated proportion of TB cases with MDR/RR-TB, 2018

- % with known HIV status: 81%
- % pulmonary: 85%
- % bacteriologically confirmedººº: 73%
- % children aged 0-14 years: 2%
- % women: 35%
- % men: 63%

Universal health coverage and social protection

TB treatment coverage (notified/estimated incidence), 2018: 87% (75–100)

TB patients facing catastrophic total costs: 5% (4–6)

TB case notification, 2018

- % tested with rapid diagnostics at time of diagnosis: 81%
- % with known HIV status: 81%
- % pulmonary: 85%
- % bacteriologically confirmedººº: 73%
- % children aged 0-14 years: 2%
- % women: 35%
- % men: 63%

Patients with known HIV status who are HIV-positive:
- on antiretroviral therapy: 1,319 (6%)

Drug-resistant TB care, 2018

- % of bacteriologically confirmed TB cases tested for rifampicin resistance ººº: 78%
  - New cases: 78%
  - Previously treated cases: 78%

Laboratory-confirmed cases*

- MDR/RR-TB: 192
- XDR-TB: 1

Patients started on treatment**

- MDR/RR-TB: 137
- XDR-TB: 1

MDR/RR-TB cases tested for resistance to second-line drugs: 145

Treatment success rate and cohort size

New and relapse cases registered in 2017: 81% (24,810)

Previously treated cases, excluding relapse, registered in 2017: 52% (704)

HIV-positive TB cases registered in 2017: 58% (1,302)

MDR/RR-TB cases started on second-line treatment in 2016: 49% (71)

XDR-TB cases started on second-line treatment in 2016: 0

TB preventive treatment, 2018

- % of HIV-positive people (newly enrolled in care) on preventive treatment: 38%

- % of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment: 88% (65–100)

TB financing, 2019

- National TB budget (US$ millions): 16

Funding source: 100% domestic, international, 0% unfunded

Ranges represent uncertainty intervals
º MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
ºº Calculated for pulmonary cases only
* Includes cases with unknown previous TB treatment history
** Includes patients diagnosed before 2016 and patients who were not laboratory-confirmed

Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries. Generated: 2019-12-21

Data: www.who.int/tb/data